近日，研究中心硕士生相余的一篇论文“Mapping the patent landscape of TROP2-targeted biologics through deep learning”被Nature Biotechnology（JCR一区，影响因子33.1）录用。（论文链接地址：https://www.nature.com/articles/s41587-025-02626-8）
论文摘要：背景：TROP2是一种参与钙信号转导的跨膜糖蛋白，在多种肿瘤中表达。它是一个有吸引力的癌症治疗靶点。本研究旨在分析TROP2生物制剂专利的全球格局，为研究和政策提供信息。方法：利用Derwent专利数据库、描述性统计、社会网络方法和深度学习方法，对全球5772项TROP2生物制剂相关专利进行综合研究。结果：近二十年来，TROP2生物制剂专利数量快速增长。专利发明人的性别不平衡，男性主导了研究和创新工作。美国的申请人、受让人和专利局持有的TROP2生物制剂专利数量最多。商业受让人倾向于深入合作，并贡献了最多的专利。除了已上市的知名TROP2抗体药物偶联物外，多种生物制剂技术也在蓬勃发展。此外，TROP2生物制剂专利质量模型的准确率达到82.9%，能够在专利公布的初始阶段识别出高质量专利。结论：TROP2生物制剂相关专利数量的快速增长加剧了行业竞争，可能会造成知识壁垒，阻碍发展。TROP2抗体药物偶联物在与其他抗肿瘤药物联合使用时表现出协同抗肿瘤作用，但其未知因素，如潜在的毒性覆盖，构成了重大挑战。本文提出的专利质量模型为企业并购、投资决策和业务规划提供了重要的支持。
Abstract：Background: TROP2 is a transmembrane glycoprotein involved in calcium signal transduction and is expressed in various tumor types. It is an attractive target for cancer therapy. This study aims to analyze the global landscape of TROP2 biologics patents to inform research and policy.Methods: Using the Derwent patent database, descriptive statistics, social network method, and deep learning methods, this paper conducted a comprehensive study on 5772 TROP2 biologics-related patents worldwide. Results: In the past two decades, the number of TROP2 biologics patents has grown rapidly. There was an imbalance in the gender of patent first inventors, with men dominating research and innovation efforts. Applicants, assignees, and patent offices in the United States held the most significant number of TROP2 biologics patents. Commercial assignees tended to collaborate deeply and contributed the most patents. Multiple biologics technologies were booming besides well-known marketed ADCs. In addition, the TROP2 biologics quality patent model achieved an accuracy of 82.9%, which could identify high-quality patents at the initial stage of patent publication. Conclusions: The rapid growth of patents related to TROP2 biologics has intensified industry competition, which may hinder development due to the knowledge barriers it creates. TROP2 ADCs exhibit synergistic antitumor effects when combined with other antitumor agents, yet their unknown factors, such as potential toxic overlay, pose a significant challenge. The patent quality model proposed in this paper provides crucial support for corporate mergers, investment decisions, and business planning.